Search

Luis Miguel Chinchilla-Tábora,1 Javier Ortiz Rodríguez-Parets,1 Álvaro Otero-Rodríguez,2 Laura Ruiz Martín,2 Juan Carlos Paniagua Escudero,3 Luis Miguel Navarro Martín,4 Belén Cigarral García,4 Adelaida Nieto Palacios,5 Idalia González Morais,1 José María Sayagués,1 María Dolores Ludeña de la Cruz1 1Department of Pathology, University Hospital of Salamanca and Institute for Biomedical Research of Salamanca, Salamanca, Spain; 2Department of Neurosurgery, University Hospital of Salamanca and Institute for Biomedical Research of Salamanca, Salamanca, Spain; 3Department of Radiology, University Hospital of Salamanca and Institute for Biomedical Research of Salamanca, Salamanca, Spain; 4Department of Clinical Oncology, University Hospital of Salamanca and Institute for Biomedical Research of Salamanca, Salamanca, Spain; 5Department of Radiation Oncology, University Hospital of Salamanca and Institute for Biomedical Research of Salamanca, Salamanca, SpainCorrespondence: Luis Miguel Chinchilla-Tábora, Department of Pathology, University Hospital of Salamanca and Institute for Biomedical Research of Salamanca, Paseo de San Vicente, 58-182, Salamanca, PC. 37007, Spain, Tel +34 923291100. Extension: 56738, Email lmct@usal.esAbstract: Hemangioblastoma (HB) is a Central Nervous System (CNS) tumor with a generally favorable behavior and prognosis, classified as WHO grade 1. Sporadic HB is not related to any inherited disease, and it usually appears in a single location. Sporadic or VHL-related HBs show variable patterns of growth velocity. Cases of growing HB can cause mild symptoms such as headache, but some cases develop serious complications such as accumulation of cerebrospinal fluid in the brain with secondary neurological damage sometimes being irreversible when early treatment is not started. Our case showed some clinical characteristics more frequently observed in VHL-related HB rather than sporadic HB, and the presence of alterations in MDM2 and EGFR that could be related to the oncogenesis of these tumors. Even when the treatment of choice for HB is surgery, the presence of these genetic alterations could open a new window for research aimed at assessing the possibility of new therapies with TKIs-EGFR and anti-MDM2 inhibitors in those HB cases with multifocal recurrences or cases with an adverse clinical behavior.Keywords: haemangioblastoma, mouse double minute 2, epidermal growth factor receptor, hydrocephalus, immunohistochemistry, fluorescence in situ hybridization

Alicia Habernau Mena,1,* Ismael García-Moguel,2,3,* María Vazquez de la Torre Gaspar,4 Victoria Mugica,5 Maria Isabel Alvarado Izquierdo,6 Maria Aranzazu Jimenez Blanco,7 Mar Gandolfo-Cano,8 Mar Jiménez Lara,9 Ana Gonzalez Moreno,10 Pilar Saura Foix,11 Ana Navarro-Pulido,12 Cristina Martin-Arriscado Arroba,13 Julio Delgado Romero,14 Javier Dominguez-Ortega15 On behalf of Asthma Committee of SOCIEDAD ESPAÑOLA DE ALERGOLOGÍA E INMUNOLOGÍA CLÍNICA (SEAIC)1Department of Allergy. Complejo Hospitalario de Mérida, Mérida, Spain; 2Department of Allergy, Hospital Universitario 12 de Octubre, Madrid, Spain; 3Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas 12), Madrid, Spain; 4Department of Allergy, Hospital Universitario Infanta Leonor, Madrid, Spain; 5Department of Allergy, Hospital de la Princesa, Madrid, Spain; 6Department of Allergy, Hospital Universitario de Cáceres, Cáceres, Spain; 7Department of Allergy, Hospital Cruz Roja, Madrid, Spain; 8Department of Allergy, Hospital Universitario de Fuenlabrada, Madrid, Spain; 9Department of Allergy, Hospital de Toledo, Toledo, Spain; 10Department of Allergy, Fundación Hospital Alcorcón, Madrid, Spain; 11Department of Allergy, Consorci Sanitari de Terrassa, Terrassa, Spain; 12Allergology Clinical Management Unit (UGC), El Tomillar Hospital, Sevilla, Spain; 13Research and Science Support Unit, Instituto de investigación Biomédica del Hospital Universitario 12 de Octubre I+12, Madrid, Spain; 14Department of Allergy, Hospital Universitario Virgen Macarena, Sevilla, Spain; 15Department of Allergy, Hospital Universitario La Paz. Instituto de Investigación (idiPaz), Madrid, Spain*These authors contributed equally to this workCorrespondence: Ismael García-Moguel, Department of Allergy, Hospital Universitario 12 de Octubre, Av de Córdoba s/n, Zip code 28005, Madrid, Spain, Tel +34-645852229, Email Ismaelgmoguel@gmail.comPurpose: The acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has had a high impact on patients with chronic diseases. In the literature, there are different perspectives on asthma as comorbidity or risk factor on COVID-19 severity.Patients and Methods: The aim of this retrospective study across 13 allergy departments in Spain was to determine the severity of COVID-19 in asthmatic adults followed in allergy departments and its relationship with atopy, clinical and demographic characteristics, phenotypes and laboratory data. In addition, lung function test and asthma control test (ACT) before and after COVID-19 were analyzed. Data was obtained from electronic medical records from March 2020 to April 2021.Results: Two hundred one asthmatic patients were diagnosed with COVID-19 infection by validated detection test. About 30% of the patients were admitted for bilateral pneumonia. Advanced age, elevated D-dimer, lower numbers of lymphocytes and eosinophils, heart diseases and hypertension were associated with severe COVID-19. Allergic and mixed allergic/eosinophilic phenotype and their biomarkers (total IgE, aeroallergens sensitizations, allergic rhinitis, and blood eosinophilia) were related to fewer hospital admissions. Poor control and lower forced expiratory volume in the first second (FEV1) were related to worse prognosis of COVID-19.Conclusion: Asthmatic patients with allergic and eosinophilic phenotype have a better evolution of COVID-19 and lower risk of admissions. Older patients, cardiovascular comorbidities, AERD and eosinopenia are related to severity COVID-19.Keywords: COVID-19, allergic asthma, eosinophils, asthma phenotype, SARS-CoV-2

In the work, an analysis of the phase formation process proceeding in a quaternary red clay-low-melting cullet-iron oxide (Fe2O3)-WAS (waste activated sludge) system in treatment at 1000oC in air has been performed. It has been established that, in sintering of the mixtures, porous ceramics consisting of a glass phase alloyed with iron ions with inclusions of cristobalite, iron-containing silicates of complex composition, α-Fe2O3, and an insignificant amount of Fe3O4 forms. The porous glass ceramics meets the compressive strength requirements imposed on building bricks.

Paracetamol intoxication is one of the causes of elevated procalcitonin concentrations unrelated to infection. We report a case series of two patients intoxicated with paracetamol whose laboratory data revealed a significant elevation of serum procalcitonin concentrations without clinical, radiological and/or biological evidence of infection. The underlying mechanism by which paracetamol triggers an increase in procalcitonin concentrations is still unclear.

La intoxicación por paracetamol es una de las causas no infecciosas asociada al incremento de la concentración de procalcitonina. Presentamos dos casos de pacientes ingresados por intoxicación por paracetamol en el que los datos analíticos revelaron un aumento significativo de procalcitonina sin datos clínicos, radiológicos y/o microbiológicos de infección. El mecanismo que explicaría este incremento no ha sido aclarado.

Scimitar Syndrome is a rare congenital disorder and a variant of partial anomalous pulmonary venous connection (PAPVC) in which part or even the entire right lung is drained by right pulmonary veins that connect anomalously to the Inferior Vena Cava (IVC). It has various presentations including exertional dyspnea, recurrent chest infection, pulmonary artery hypertension, and hemoptysis. The initial diagnosis of PAPVC may be made by echocardiography and is typically confirmed by magnetic resonance imaging, computed tomography, or cardiac catheterization.We report a 69-year-old man with progressive dyspnea on exertion associated with palpitations of five years of evolution. The patient was diagnosed with cardiomyopathy, pulmonary hypertension and was started on treatment with anticoagulation, digoxin, and metoprolol for his atrial fibrillation. Despite the treatment, the dyspnea did not improve. The patient underwent cardiac catheterization, where the anomalous venous drainage was confirmed. Scimitar syndrome was corrected by surgical intervention with complete resolution of symptoms.